Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7946

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7946). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907946)

Losartan Potassium 50 mg film-coated tablets in a bottle package labeled by A-S Medication Solutions. The label includes product NDC 50090-7946, storage instructions to keep at 68 to 77 degrees Fahrenheit away from light, and states the bottle contains 90 tablets. The label also features a QR code and instructions to see the package insert for dosage information.*

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with the primary endpoint over study months between Atenolol and Losartan Potassium. The graph shows risk reduction with Losartan Potassium compared to Atenolol, noting an adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The horizontal axis represents study months from 0 to 66, and the vertical axis shows the percentage of patients from 0 to 8. Losartan Potassium shows a lower percentage of patients experiencing stroke compared to Atenolol. The chart notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

A forest plot chart showing the hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol across various patient subgroups. The chart compares event rates for 'Primary Composite' outcomes and 'Stroke (Fatal/Non-Fatal),' displaying data by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The horizontal axis indicates whether the results favor Losartan Potassium or Atenolol based on hazard ratios.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium versus placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022. The x-axis represents time in months, and the y-axis shows the percentage of patients with the event.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

Chemical structure of Losartan Potassium, showing the arrangement of atoms including chlorine, nitrogen, potassium, and aromatic rings typical of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.